Prevalence of lower airway dysfunction in athletes: a systematic review and meta-analysis by a subgroup of the IOC consensus group on 'acute respiratory illness in the athlete'.


Journal

British journal of sports medicine
ISSN: 1473-0480
Titre abrégé: Br J Sports Med
Pays: England
ID NLM: 0432520

Informations de publication

Date de publication:
Feb 2022
Historique:
accepted: 20 10 2021
pubmed: 8 12 2021
medline: 5 2 2022
entrez: 7 12 2021
Statut: ppublish

Résumé

To report the prevalence of lower airway dysfunction in athletes and highlight risk factors and susceptible groups. Systematic review and meta-analysis. PubMed, EBSCOhost and Web of Science (1 January 1990 to 31 July 2020). Original full-text studies, including male or female athletes/physically active individuals/military personnel (aged 15-65 years) who had a prior asthma diagnosis and/or underwent screening for lower airway dysfunction via self-report (ie, patient recall or questionnaires) or objective testing (ie, direct or indirect bronchial provocation challenge). In total, 1284 studies were identified. Of these, 64 studies (n=37 643 athletes) from over 21 countries (81.3% European and North America) were included. The prevalence of lower airway dysfunction was 21.8% (95% CI 18.8% to 25.0%) and has remained stable over the past 30 years. The highest prevalence was observed in elite endurance athletes at 25.1% (95% CI 20.0% to 30.5%) (Q=293, I Lower airway dysfunction affects approximately one in five athletes, with the highest prevalence observed in those participating in elite endurance, aquatic and winter-based sporting disciplines. Further longitudinal, multicentre studies addressing causality (ie, training status/dose-response relationship) and evaluating preventative strategies to mitigate against the development of lower airway dysfunction remain an important priority for future research.

Identifiants

pubmed: 34872908
pii: bjsports-2021-104601
doi: 10.1136/bjsports-2021-104601
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

213-222

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Oliver J Price (OJ)

School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.

Nicola Sewry (N)

Sport, Exercise Medicine and Lifestyle Institute (SEMLI), Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
IOC Research Centre, Pretoria, South Africa.

Martin Schwellnus (M)

Sport, Exercise Medicine and Lifestyle Institute (SEMLI), Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
IOC Research Centre, Pretoria, South Africa.

Vibeke Backer (V)

Centre for Physical Activity Research, Rigshopitalet, Copenhagen University, Denmark, Copenhagen, Denmark.

Tonje Reier-Nilsen (T)

The Norwegian Olympic Sports Centre, Oslo, Norway.

Valerie Bougault (V)

Laboratoire Motricité Humaine Expertise Sport Santé, Université Côte d'Azur, Nice, France.

Lars Pedersen (L)

Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark.

Bruno Chenuel (B)

Centre Hospitalier Régional Universitaire de Nancy, Centre Universitaire de Médecine du Sport et Activité Physique Adaptée, Service des Explorations de la Fonction Respiratoire, Université de Lorraine, Nancy, France.
Medical Physiology, Université de Lorraine, Nancy, France.

Kjell Larsson (K)

Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.

James H Hull (JH)

Department of Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK j.hull@rbht.nhs.uk.
Division of Surgery and Interventional Science, Institute of Sport, Exercise and Health (ISEH), University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH